Cargando…
Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
BACKGROUND: Current treatment strategies for antibody-mediated renal allograft rejection (AMR) are not sufficiently effective. In most centers, “standard of care” treatment includes plasmapheresis (PPH) and IVIG preparations. Since several years, modern therapeutics targeting B cells and plasma cell...
Autores principales: | Waiser, Johannes, Duerr, Michael, Schönemann, Constanze, Rudolph, Birgit, Wu, Kaiyin, Halleck, Fabian, Budde, Klemens, Lachmann, Nils |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083001/ https://www.ncbi.nlm.nih.gov/pubmed/27819032 http://dx.doi.org/10.1097/TXD.0000000000000604 |
Ejemplares similares
-
Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step
por: Lachmann, Nils, et al.
Publicado: (2017) -
Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia
por: Joachim, Emily, et al.
Publicado: (2020) -
Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017) -
The Role of Complement Split-products as Biomarkers for Acute Antibody-mediated Rejection of Kidney Allografts
por: Abu Jawdeh, Bassam G., et al.
Publicado: (2022) -
Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome
por: van den Hoogen, Martijn W.F., et al.
Publicado: (2017)